alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT BY
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


         In connection with the Quarterly Report of White Horse Resources, Inc.,
on Form 10-QSB for the period ending June 30, 2003 as filed with the  Securities
and Exchange Commission on the date hereof (the "REPORT"),  the undersigned,  B.
Stephen Bailey,  Chief Executive Officer and Principal Accounting Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to ss.
906 of the  Sarbanes-Oxley  Act of 2002,  that to the best of my  knowledge  and
belief:

         1. The Report fully complies with the requirements of section 13 (a) or
15 (d) of the Securities Exchange Act of 1934; and

         2. The  information  contained in the Report  fairly  presents,  in all
material  respects,  the  financial  condition  and result of  operations of the
Company.


Date: April 19, 2004

/s/ B. Stephen Bailey
B. Stephen Bailey
President
(Principal Executive & Accounting Officer)


A signed  original of this written  statement  required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the  electronic  version of this written  statement
has been  provided  to the  Company  and will be  retained  by the  Company  and
furnished to the Securities and Exchange Commission or its staff upon request.
§ 636.503 Must I notify offerors of my intent to use/not use discussions? Yes, in competitive acquisitions, the solicitation must notify offerors of your intent. You should either: ( a ) Notify offerors that discussions may or may not be held depending on the quality of the proposals received (except clarifications may be used as described in § 636.401). Therefore, the offeror's initial proposal should contain the offeror's best terms from a cost or price and technical standpoint; or
( b ) Notify offerors of your intent to establish a competitive range and hold discussions.
CS 315822-M 09/17/2020

10 coisas que pode fazer para tratar os seus 

sintomas de COVID-19 em casa

Versão acessível: https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html

Se tiver COVID-19 eventual ou confirmada:

1. Mantenha-se em casa, sem 

ir ao local de emprego ou 

escola. E evite outros espaços 

públicos. Caso tenha de sair, 

evite usar qualquer tipo de 

transporte público, boleia 

ou táxis.

2. Monitorize atentamente os 

seus sintomas. Se os seus 

sintomas se agravarem, 

contacte imediatamente o 

seu profissional de saúde. 

3. Descanse e 

mantenha-se 

hidratado(a). 

4. Se tiver uma consulta 

médica, contacte o 

profissional de saúde

com antecedência e 

informe que tem ou 

pode ter COVID-19.

5. Para emergências 

médicas, contacte o 911 

e informe a equipa de 

emergência que tem ou 

pode ter COVID-19.

6. Tape a sua boca e nariz 

com um lenço ou use a 

parte interna do cotovelo.

7. Lave frequentemente 

as suas mãos com água e 

sabão durante, pelo menos, 

20 segundos ou use um 

antissético à base de álcool 

que contenha, pelo menos, 

60% de álcool. 

8. Tanto quanto possível, 

mantenha-se numa divisão 

específica e distante de 

outras pessoas e de animais 

de estimação, em sua casa. 

Também deve usar uma casa de 

banho separada, se disponível. 

Caso precise de estar perto de 

outras pessoas ou fora de casa, 

use uma máscara.

9. Evite partilhar objetos 

pessoais com outras pessoas

no seu agregado familiar, 

como pratos, toalhas e 

lençóis.

10. Limpe todas as superfícies

que são tocadas com 

frequência, como bancadas, 

mesas e maçanetas. Use 

sprays ou toalhitas de 

limpeza doméstica de acordo 

com as instruções no rótulo. 

cdc.gov/coronavirus
EX-32            >SECTION 1350 CERTIFICATION OF PAUL EGAN AND CIARAN EGAN

                         SECTION 1350 CERTIFICATION

In connection with the quarterly report of FreeStar Technology
Corporation ("Registrant") on Form 10-QSB/A for the quarter ended
December 31, 2002 as filed with the Securities and Exchange Commission
("Report"), the undersigned, in the capacities and on the dates
indicated below, hereby certify pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) that to their
knowledge:

1.  The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

2.  The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Registrant.


Dated: March 25, 2004                  By: /s/  Paul Egan
                                       Paul Egan, President


Dated: March 25, 2004                  By: /s/  Ciaran Egan
                                      Ciaran Egan, Chief Financial Officer
Desarrollando la comunidad a 

través de la salud y el bienestar.

La salud y el bienestar exigen que se cuide a la persona en forma integral: mente, cuerpo y espíritu. Pero, debido a que 

siempre estamos ocupados, es posible que nuestro bienestar sea lo último que atendemos.

Este año queremos que sea más fácil para usted y sus seres queridos poner su bienestar en primer lugar, haciendo que la 

vacunación contra la influenza esté más accesible.

La influenza puede ser una enfermedad grave, hasta para la gente sana. Todas las personas desde los 6 meses en adelante 

deben vacunarse contra la influenza todos los años.

Proteja a su familia, congregación y por ti mismo de recibir la vacuna contra la influenza.

Mente. Espíritu.

Cuerpo.

Si quiere saber más, 

visite www.cdc.gov/flu 

(Seleccione “En 

Español”) o llame al 

1-800-232-4636 .Información de la clinica/logo aquí

Departamento de 

Salud y Servicios Humanos

Centros para el Control y la 

Prevención de Enfermedades

Para más información en español visite: 

http://www.cdc.gov/flu/

CS226325-B
#### § 1204.1 Single level of appellate review.

The decision of the Board of Immigration Appeals concerning the denial of a relative visa petition under 8 CFR chapter I, part 204 because the petitioner failed to establish eligibility for the bona fide marriage exemption contained in that part will constitute the single level of appellate review established by statute.
UNITED STATES OF AMERICA

Before the

SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934 

Release No. 97916 / July 17, 2023

ADMINISTRATIVE PROCEEDING

File No. 3-20906

In the Matter of

Geluk Capital Management Ltd 

and Douglas Gerald Fathers,

Respondents.

:

:

:

:

:

:

:

ORDER APPOINTING 

TAX ADMINISTRATOR

On May 4, 2022, the Commission issued an Omnibus Order Directing the Engagement of 

Two Tax Administrators for Appointment on a Case-By-Case Basis in Administrative 

Proceedings that Establish Distribution Funds (the “Omnibus Order”).1 The Omnibus Order 

engaged Miller Kaplan Arase LLP and Heffler, Radetich & Saitta, LLP to serve as the 

Commission’s tax administrator (“Tax Administrator”), for selection and appointment on an 

individual case basis, for calendar years 2022 through 2024 in administrative proceedings where 

the distribution fund may incur tax-related obligations as a Qualified Settlement Fund (“QSF”) 

under the Department of the Treasury Regulation § 1.468B-1(c). 

The Director of the Division of Enforcement is authorized to appoint a Tax Administrator 

pursuant to the Omnibus Order.2 The Commission staff has requested the appointment of 

Heffler, Radetich & Saitta, LLP as the Tax Administrator for the QSF in the above-referenced 

proceeding.

1

 Exchange Act Rel. No. 94845 (May 4, 2022).

2

 See Delegation of Authority to Director of the Division of Enforcement, Securities Act Rel. No. 10900 (Dec. 10, 

2020).
2

Accordingly, IT IS ORDERED that, pursuant to the Omnibus Order, Heffler, Radetich & 

Saitta, LLP is appointed as the Tax Administrator for the QSF in the above-referenced proceeding.

For the Commission, by the Division of Enforcement, pursuant to delegated authority.3

Vanessa A. Countryman

Secretary 

3

 17 C.F.R. § 200.30-4(a)(21)(ii).
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE FINANCIAL STATEMENTS OF REGENCY EQUITIES CORP. FOR THE
PERIOD ENDED DECEMBER 31, 1998 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTES.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                       3,113,031
<SECURITIES>                                         0
<RECEIVABLES>                                    3,412
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             3,116,443
<PP&E>                                       1,256,441
<DEPRECIATION>                                 392,544
<TOTAL-ASSETS>                               3,980,340
<CURRENT-LIABILITIES>                           33,569
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       872,836
<OTHER-SE>                                   3,073,935
<TOTAL-LIABILITY-AND-EQUITY>                 3,980,340
<SALES>                                              0
<TOTAL-REVENUES>                               198,158
<CGS>                                                0
<TOTAL-COSTS>                                  127,953
<OTHER-EXPENSES>                               152,069
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (81,864)
<INCOME-TAX>                                     2,220
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (84,084)
<EPS-PRIMARY>                                   (.001)
<EPS-DILUTED>                                   (.001)
        

</TABLE>
Exhibit 2

Case 17-03348-KRH Doc 1-2 Filed 05/03/17 Entered 05/03/17 22:07:11 Desc 

 Exhibit 2 Page 1 of 2
Payment Number Payment Date Payment Amount

Payment Listing for Doctors of Northport Primary Medical Care

Health Diagnostic Laboratory, Inc.

41174 1/30/2013 $800.00

42977 2/11/2013 $1,640.00

44861 3/6/2013 $2,380.00

47235 4/8/2013 $1,800.00

49447 5/7/2013 $1,400.00

51943 6/6/2013 $1,420.00

54241 7/5/2013 $1,760.00

54896 7/18/2013 $40.00

56717 8/5/2013 $1,620.00

59246 9/5/2013 $1,200.00

61659 10/8/2013 $1,420.00

64151 11/5/2013 $1,500.00

66906 12/3/2013 $1,060.00

67929 12/16/2013 $60.00

69699 1/7/2014 $1,240.00

72238 2/11/2014 $1,360.00

74555 3/6/2014 $1,080.00

77012 4/4/2014 $1,380.00

78301 4/18/2014 $20.00

80058 5/5/2014 $560.00

82750 6/5/2014 $540.00

85412 7/14/2014 $640.00

$24,920.00

Case 17-03348-KRH Doc 1-2 Filed 05/03/17 Entered 05/03/17 22:07:11 Desc 

 Exhibit 2 Page 2 of 2
CS 315822-W 06/24/2020

10 ສິ່ງທີ່ທ່ານສາມາດເຮັດໄດ້ເພື່ອຈັດການ

ອາການໂຄວິດ-19 ຂອງທ່ານຢູ່ທີ່ບ້ານ

ເວຊີນ່ັທ່ີສາມາດເຂົ້າເຖງິໄດ: 

້https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html

ຖ້າຫາກທ່ານອາດຈະເປັນ ຫຼືຢືນຢັນວ່າເປັນໂຄວິດ-19 (COVID-19):

1. ພັກວຽກ ແລະ ໂຮງຮຽນຢູເຮ່ ອນື . 

ແລະ ຢູຫ່ າງ່ ຈາກສະຖານທ່ີສາທາລະ

ນະ. ຖາ້ຫາກທານ່ ຕອງ້ ອອກໄປຂາງ້

ນອກ, ຫຼີກລຽງການ ້ ນໍາ�ໃຊລະ້ ບບົຂນົ

ສ່ງົສາທາລະນະ, ການຂ່ລີດົຮວມ່ ກນັ

ຫຼືຂ່ແທີ ັກຊ່ທຸກີ ຊະນດິ .

2. ຕິດຕາມອາການຂອງທ່ານຢາງ່

ລະມດັລະວງັ. ຖາ້ຫາກອາການຂອງ

ທານ່ ຮຸນແຮງຂນຶ້ , ໂທຫາຜູໃຫ້ ບ້ ໍລິ

ການເບ່ງິແຍງດູແລສຸຂະພາບຂອງ

ທານ່ ທນັທີ. 

3. ພັກຜ່ອນ ແລະ ດື່ມນ�້ໍາ

ຕະຫຼອດ. 

4. ຖາ້ຫາກທານ່ ມການ ີ ນດຫມາຍ ັ

ທາງການແພດ, ໂທຫາຜູ້ໃຫ້ບລິ ໍ

ການເບິ່ງແຍງດູແລສຸຂະພາບ

ກອນ່ ເວລາ ແລະ ບອກພວກເຂົາ

ວາ່ ທາ່ ນອາດຈະເປັນໂຄວດິ -19 

(COVID-19).

5. ສໍາ�ລບເຫດການ ັ ສຸກເສນີທາງ

ການແພດ, ໂທ 911 ແລະ

ແຈ້ງເຈົ້າຫນ້າທີ່ຈັດສົ່ງວາ່

ທານ່ ອາດຈະເປັນໂຄວດິ 19 

(COVID-19).

6. ປິດການໄອ ແລະ ຈາມຂອງ

ທ່ານດວຍເຈ ້ ຍທ້ ິດຊູຫຼືໃຊຂ້ ສອກ ໍ

້

ດານ້ ໃນຂອງທານ່ .

7. ຫມັ່ນລ້າງມືຂອງທ່ານດວຍ້ ສະບູ່ແລະ

ນໍາ�

້ເປັນເວລາຢາງ່ ຫນອຍ້ 20 ວນາິ ທີຫຼືນໍາ�

ໃຊເຈວ ້ ຫຼືນໍາ�

້ຢາລາງ້ ມທື່ີມສີວນ່ ປະສມົ

ຂອງທາດເຫົ້

ຼາຢາງ່ ຫນອຍ້ 60%. 

8. ໃຫ້ພັກຢູ່ໃນຫອງ້ ສະເພາະ ແລະ ຫ່າງ

ຈາກຄົນອື່ນຢູໃນ່ ເຮອນື ຂອງທານ່ ໃຫ້

ຫຼາຍເທ່ົາທ່ີຈະເຮັດໄດ. 

້ນອກນນທັ້ ານ່

ຄວນຈະໃຊຫ້ ອງ້ ນໍາ�

້ແຍກ, ຖາ້ມ. ີຖາ້ຫາກ

ທານ່ ຕອງ້ ຢູໃກ່ ຄ້ ນົອ່ນໃນ ື ຫຼືນອກບານ້ , 

ໃສຜ່ າ້ປິດປາກປິດດງັ.

9. ຫຼີກລ້ຽງການໃຊ້ເຄື່ອງຂອງສ່ວນ

ຕົວຮ່ວມກັນກບັຄນົອ່ນື ໃນເຮືອນ

ຂອງທານ່ ເຊ່ັນ: ຈານ່ , ຜາ້ເຊັດໂຕ

ແລະ ຜາ້ປູບອນນອນ ່ .

10. ອະນາໄມພື້ນຜິວທ່ີຖກືສໍາ�ຜດັຕະ

ຫຼອດເຊ່ັນ: ເຄົາເຕ, ີຫນາ້ໂຕະ ແລະ

ລູກບດິ ປະຕຸ. ໃຊສະ້ ເປທໍາ�ຄວາມສະ

ອາດຫຼືຜາເຊ ້ ັດອະນາໄມເຮອນື ຕາມຄໍາ�

ແນະນໍາ�ໃນປ້າຍບອກ. 

cdc.gov/coronavirus
Case 16-10881-RGM    Doc 28    Filed 05/25/16    Entered 05/25/16 10:48:12    Desc Main Document      Page 1 of 4

Case 16-10881-RGM    Doc 28    Filed 05/25/16    Entered 05/25/16 10:48:12    Desc Main Document      Page 2 of 4

Case 16-10881-RGM    Doc 28    Filed 05/25/16    Entered 05/25/16 10:48:12    Desc Main Document      Page 3 of 4

Case 16-10881-RGM    Doc 28    Filed 05/25/16    Entered 05/25/16 10:48:12    Desc Main Document      Page 4 of 4
Medicine & 

 Pregnancy

Pregnancy can be an exciting 

time. However, this time can also 

make you feel uneasy if you are 

not sure how your medicines will 

affect your baby. Not all medicines 

are safe to take when you are 

pregnant. Even headache or pain 

medicine may not be safe during 

certain times in your pregnancy.

FDA Office of Women’s Health 

www.fda.gov/pregnancy

Here are 4 tips to help you learn more 

about how prescription and over-thecounter medicines might affect you 

and your baby:

Ask Questions

Always talk to your doctor, nurse, or 

pharmacist before you start taking any 

medicines, herbs, or vitamins. Don’t stop 

taking your medicines unless your healthcare 

provider says that it is OK.

Use These Questions:

• Will I need to change my medicine if I want

to get pregnant?

• How might this medicine affect my baby?

• What medicines and herbs should I avoid?

• Will I need to take more or less of my medicine?

• What kind of vitamins should I take?

• Can I keep taking this medicine when I start 

breastfeeding?

Read the Label

Check the drug label and 

other information you get with your 

medicine to learn about the possible 

risks for women who are pregnant or 

breastfeeding.

The labeling tells you what is known about how 

the medicine might affect pregnant women. Your 

healthcare provider can help you decide if you 

should take the medicine.
Medicine & Pregnancy

FDA Office of Women’s Health 

www.fda.gov/pregnancy

2016

Be Smart Online

Ask your doctor, nurse, 

or pharmacist about the 

information you get online.

Some websites say certain drugs are safe to 

take during pregnancy but you should check 

with your healthcare provider first. Every 

woman’s body is different. It may not be safe 

for you. 

• Do not trust that a product is safe just 

because it says “natural.” 

• Check with your healthcare provider before 

you use a product that you heard about in a 

chat room or group.

Report Problems

First, tell your healthcare 

provider about any 

problems you have with your 

medicine. Also, tell FDA about 

any serious problems you have 

after taking a medicine.

• Call 1-800-FDA-1088 to get a 

reporting form sent to you by mail.

• Report Problems Online: 

www.fda.gov/MedWatch/report

Sign Up for a Pregnancy Registry

Pregnancy Exposure Registries are research studies that get information from women who take 

prescription medicines or get a vaccine during pregnancy. Pregnancy registries help women and their 

doctors learn more about how medicines can be safely used during pregnancy.

• Help other pregnant women by sharing your experiences with medicines.

• You will not be asked to take any new medicines.

• You will provide information about your health and your baby’s health.

FDA does not run pregnancy registry studies, but it keeps a list of registries.

See if there is a registry for your medicine at: www.fda.gov/pregnancyregistries
#### § 140.606 Project agreements.

Project Agreements, Form PR-2, shall be prepared and executed. Agreement provision 8 on the reverse side of Form PR-2[1] shall apply for bond issue projects.

###### Footnotes -
  140.606

[1] The text of FHWA Form PR-2 is found in 23 CFR part 630, subpart C, appendix A.
### §482m. Teton National Forest in Wyoming; additional lands

The following-described lands of the Jackson Hole National Monument are made a part of the Teton National Forest and shall be administered hereafter in accordance with the laws applicable to said forest:

### sixth principal meridian

Township 45 north, range 113 west: Section 21, lot 5; section 22, lots 2 and 6; section 23, lot 3; section 26, lots 2, 3, 6, 7, southwest quarter northwest quarter, southwest quarter and southwest quarter southeast quarter; section 27, lots 1, 2, 4, 6, 7, 8, 9, southeast quarter northeast quarter and south half; section 28, lot 1, southeast quarter northeast quarter and east half southeast quarter; section 29, lots 2, 4, 5, 6, 8, southwest quarter northeast quarter, northwest quarter southeast quarter, south half northwest quarter, and north half southwest quarter; section 30, lot 7, south half northeast quarter, north half southeast quarter and southeast quarter southeast quarter; section 31, lots 1 and 2; section 32, lots 2 and 5; section 33, east half northeast quarter and northeast quarter southeast quarter; section 34, north half and north half south half; section 35, north half, containing in all two thousand eight hundred six and thirty-four one-hundredths acres, more or less.

(Sept. 14, 1950, ch. 950, §3, 64 Stat. 850.)

#### **Editorial Notes**

#### References in Text

The Jackson Hole National Monument, referred to in text, was created in Wyoming by Presidential Proc. No. 2578, Mar. 15, 1943, 57 Stat. 731. For provisions transferring other lands of such former national monument, see sections 406d–1 and 673b of this title.

#### **Statutory Notes and Related Subsidiaries**

#### Revocation of Temporary Withdrawals of Public Lands

Revocation of temporary withdrawals of public lands in aid of legislation pertaining to parks, monuments, etc., adjacent to Grand Teton National Park in Wyoming, see note under section 406d–1 of this title.

#### Repeal of Inconsistent Laws

Repeal of laws inconsistent with act Sept. 14, 1950, see note set out under section 406d–1 of this title.
STANDARD REVIEW ENGINEERING REPORT

PMN: 05-0774

Standard Review Draft 3/13/07

ENGINEER: Hall \ MAD PV (kg/yr):

Revision Notes / Assessment Overview: This case was placed into Standard Review to address Human Health

concerns. The submitter has provided information (fax 2/12/2007) indicating that

SUBMITTER

USE:

OTHER USES:

MSDS: Yes Label: No

Gen Eqpt:

Respirator:

Health Eff ects:

TLV/PEL:

CRSS (09/19/2005):

Chemical Name:

S-H20:

VP:

MW:Physical State and Misc CRSS Info: Neat: Mfg:

Proc/For m: End Use:

Consumer Use:

SAT (concerns) (09/20/2005): Migration to groundw ater: Moderate PBT rating: P2B1T2 Health: 2 Dermal, Drinking Water, Inhalation,

Eco: 2 Water (All releases to water with a CC = 2 ppb.),

OCCUPATIONAL EXPOSURE RATING: 1A

NOTES & KEY ASSUMPTIONS: Generated by the 06/07/2005 version of ChemSTEER.

POLLUTION PREVENTION CONSIDERATIONS:INITIAL REVIEW ENGINEERING REPORT

PMN: 05-0774

Number of Sites/ Location:
Bayer Days/yr:

Basis:

Process Description:

ENVIRONMENTAL RELEASE S ESTIMATE SUMMARY IRER Note: The daily releases listed for any source below may coincide with daily rele ases from the other sources

to the same medium.

Output :

to:

from:

basis:

Output:

to:

from:

basis:

Output:

to:

from:

basis:RELEASE TOTAL kg/yr - all sites

OCCUPATIONAL EXPOSURES ESTIMATE SUMMARY Tot. # of workers expose d via assessed routes:

Basis:

Inhalation:

Dermal:

Exposure to at concentration High End: Number of workers (all sites) with dermal exposure:

BasisINITIAL REVIEW ENGINEERING REPORT

PMN: 05-0774

Number of Sites/ Location:

Days/yr:

Basis:

Process Description:

ENVIRONMENTAL RELEASE S ESTIMATE SUMMARY IRER Note: The daily releases listed for any source below may coincide with daily rele ases from the other sources

to the same medium.

from:

basis:

to:

from:

basis:

.

RELEASE TOTAL kg/yr - all sites

OCCUPATIONAL EXPOSURES ESTIMATE SUMMARY Tot. # of workers expose d via assessed routes:Basis:

Inhalation:

Dermal:

Exposure to at concentration High End: Number of workers (all sites) with dermal exposure:

Basis:CALL BY: Organization:

CALL TO:

Organization:

Date:

Time:

Phone:

-
#### In the Matter of the Accounting of Robert B. Bergman, Guardian of George R. Bunting, an Infant. Emma J. Bergman, as Administratrix of the Estate of Robert E. Bergman, Deceased, et al., Appellants; George R. Bunting, Respondent. In the Matter of the Accounting of Robert E. Bergman, as Executor of Katherine L. Bunting, Deceased. Emma J. Bergman, as Administratrix of the Estate of Robert E. Bergman, Deceased, Appellant; George R. Bunting, Respondent. In the Matter of the Accounting of Robert E. Bergman, as Trustee under the Will of Harry F. L. Bunting, Deceased. Emma J. Bergman, as Administratrix of the Estate of Robert E. Bergman, Deceased, Appellant; George R. Bunting, Respondent.

No opinion.—Present — Martin, P. J., Untermyer, Dore, Cohn and Callahan, JJ.